Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 4/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.37 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
| ▸ | PTPRF | P10586 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6192110 | 0.93 | LCK (0.38) | LCKPTPN1BRD9CA1CA2 | |
| SCHEMBL3610995 | 0.87 | LCK (0.41) | LCKCA1CA2RXFP1METAP1 | |
| SCHEMBL101455 | 0.87 | RAF1 (0.42) | LCK | |
| SCHEMBL22774869 | 0.83 | LCK (0.41) | LCKBRD9CA1CA2CYP17A1 | |
| SCHEMBL21712632 | 0.83 | CTSS (0.48) | CA2 | |
| SCHEMBL21712631 | 0.83 | CTSS (0.48) | CA2 | |
| SCHEMBL668558 | 0.82 | RAF1 (0.49) | RXFP1 | |
| SCHEMBL22774665 | 0.82 | LCK (0.43) | LCKBRD9CA1CA2CYP17A1 | |
| SCHEMBL28449432 | 0.82 | CTSS (0.47) | — | |
| SCHEMBL22774510 | 0.81 | LCK (0.40) | LCKBRD9CA1CA2CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112661770-B | Compound and method for preparing substituted [5,6] cyclo-4 (3H) -pyrimidone compound by using same | 南京正济医药研究有限公司 | 2022-11-08 | — | — | CN | disclosed |
| WO-2022134147-A1 | COMPOUND AND METHOD FOR PREPARING SUBSTITUTED [5,6]CYCLIC-4(3H)-PYRIMIDONE COMPOUND FROM SAME | 南京正济医药研究有限公司 | 2022-06-30 | — | — | WO | disclosed |
| CN-112661770-A | Compound and method for preparing substituted [5,6] ring-4 (3H) -pyrimidone compound by using same | 南京正济医药研究有限公司 | 2021-04-16 | — | — | CN | disclosed |
| CN-112409373-A | Substituted [5,6] cyclo-4 (3H) -pyrimidinones as anticancer agents | 南京正济医药研究有限公司 | 2021-02-26 | — | — | CN | disclosed |
| CN-110381950-B | Substituted [5,6] cyclo-4 (3H) -pyrimidinones as anticancer agents | 南京正济医药研究有限公司 | 2020-09-04 | — | — | CN | disclosed |
| US-10745410-B2 | Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents | ZENJI RESEARCH LABORATORIES (CN) | 2020-08-18 | — | — | US | disclosed |
| US-20200055867-A1 | SUBSTITUTED [5,6]CYCLIC-4(3H)-PYRIMIDINONES AS ANTICANCER AGENTS | ZENJI RESEARCH LABORATORIES (CN) | 2020-02-20 | — | — | US | disclosed |
| WO-2018217439-A1 | SUBSTITUTED [5,6]CYCLIC-4(3H)-PYRIMIDINONES AS ANTICANCER AGENTS | ZHANG HAI JUN (US) | 2018-11-29 | — | — | WO | disclosed |
| EP-1987042-B1 | NOVEL AMINO ALCOHOL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI SA (FR) | 2015-01-21 | — | — | EP | disclosed |
| US-8853208-B2 | Amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments | SANOFI (FR) | 2014-10-07 | — | — | US | disclosed |
| WO-2007093365-A2 | NOVEL AMINO ALCOHOL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (DE) | 2007-08-23 | — | — | WO | disclosed |
| EP-1421079-B1 | THIOPHENYL COMPOUNDS AS MEDICAMENTS | ASTRAZENECA AB (SE) | 2007-02-07 | — | — | EP | disclosed |
| US-7098240-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-08-29 | — | — | US | disclosed |
| US-20060111431-A1 | Thiophene carboxanmides as inhibitors of the enzyme ikk-2 | ASTRAZENECA AB (SE) | 2006-05-25 | — | — | US | disclosed |
| US-20060058522-A1 | Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| EP-1583755-A1 | THIOPHENE-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZIME IKK-2 | AstraZeneca AB (SE) | 2005-10-12 | — | — | EP | disclosed |
| US-20040235821-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | US | disclosed |
| WO-2004063186-A1 | THIOPHENE-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZIME IKK-2 | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | WO | disclosed |
| EP-1421079-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003010163-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058522-A1 | Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 | NFKBIA, RELA, IKBKE | LCK 226/4885PTPN1 1070/4885BRD9 556/4885 |
| US-20200055867-A1 | SUBSTITUTED [5,6]CYCLIC-4(3H)-PYRIMIDINONES AS ANTICANCER AGENTS | CDC7, CDK7, CDK17 | LCK 1029/4885PTPN1 3174/4885BRD9 1617/4885 |
| US-20060111431-A1 | Thiophene carboxanmides as inhibitors of the enzyme ikk-2 | RELA, NFKBIA, CHUK | LCK 373/4885PTPN1 1391/4885BRD9 587/4885 |
| US-10745410-B2 | Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents | CDC7, CDK7, CDK17 | LCK 1029/4885PTPN1 3174/4885BRD9 1617/4885 |
| US-20040235821-A1 | Novel compounds | ABCG2, UGT1A1, SULT1E1 | LCK 2825/4885PTPN1 2491/4885BRD9 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.